Telehealth Buprenorphine Prescribing Rules in 2026

Direct answer: Federal rules provide a telemedicine pathway for an authorized practitioner to prescribe buprenorphine for opioid use disorder to a patient who has not had an in-person evaluation. SAMHSA says the pathway permits up to a total six-month supply through audio-video or, with documentation, audio-only encounters. Further prescribing requires an in-person medical visit or another mechanism allowed by DEA. Stricter state rules still control.

This is a general summary, not legal advice or a promise that a prescription can be issued. Federal and state requirements, patient location, clinician credentials, clinical findings, documentation, pharmacy decisions, and later regulatory changes all matter.

Federal pathway at a glance

| Question | General federal rule described by SAMHSA | Important caveat | |---|---|---| | Can a new patient be evaluated remotely? | Yes, under the buprenorphine telemedicine pathway | The practitioner must meet all applicable federal and state requirements | | Is video always required? | Audio-video or audio-only may be used | The reason for audio-only should be documented | | How long can remote prescribing continue before another pathway is needed? | Up to a total six-month medication supply under this pathway | Further prescribing requires an in-person visit or another DEA-authorized mechanism | | Is a PDMP check required? | SAMHSA instructs practitioners to check the state PDMP before prescribing and document the check or attempt | State requirements may be more specific or stricter | | Does the pathway guarantee medication? | No | Prescribing remains an individual clinical decision |

Who does the rule address?

The special buprenorphine pathway matters when a patient has never received an in-person medical evaluation from the prescribing practitioner and the practitioner is considering a controlled-substance prescription for OUD through telemedicine.

DEA explains that its telemedicine controlled-substance rules do not apply in the same way once a patient has had an in-person evaluation by the relevant medical provider. The exact regulatory relationship and record should be confirmed by the practitioner or compliance team.

The six-month total is not a six-month prescription guarantee

SAMHSA describes a total of up to six months of medication supply through this pathway. That does not require a clinician to prescribe six months at once, continue treatment for six months, or prescribe after every visit. Prescription duration and follow-up remain subject to clinical judgment, controlled-substance rules, state law, insurance, and pharmacy dispensing.

Before the pathway is exhausted, the provider and patient should discuss the next legally available step. That may involve an in-person medical visit or another mechanism recognized by DEA. A website should not promise that indefinite controlled-substance prescribing will remain remote.

Audio-only visits

SAMHSA states that audio-only telemedicine may be used even when video exists, but the reason for choosing audio-only should be documented in the medical record. Programs should also evaluate whether audio-only communication allows a clinically adequate assessment in the particular case and whether state rules impose additional requirements.

Accessibility and digital-equity needs deserve thoughtful accommodation, but they do not remove documentation, identity, licensure, privacy, or clinical-safety obligations.

PDMP and records

For patients who have not had an in-person visit, SAMHSA identifies a prescription drug monitoring program check before prescribing as a key requirement and instructs practitioners to document the date and time of the check or attempted check. Programs should maintain a clear workflow for:

• confirming the patient’s physical location
• verifying identity
• checking the correct state PDMP
• documenting an unavailable PDMP or failed attempt
• recording the encounter modality and reason for audio-only use
• tracking the total medication supply issued under the pathway
• planning the transition before the six-month limit is reached

This list is operational context, not a substitute for the rule or legal review.

State law can be stricter

Federal law is the baseline. The practitioner must also follow the requirements of the state where the patient is located and the rules governing that practitioner’s license and prescribing authority. Relevant requirements may involve licensure, establishing a practitioner-patient relationship, telehealth consent, PDMP use, documentation, prescribing standards, collaborating or supervising arrangements, and pharmacy practice.

Grata offers telehealth services in Virginia, Ohio, and Pennsylvania, but this article does not make a blanket legal conclusion for every practitioner type or patient circumstance in those states. Current requirements should be checked with the appropriate state authority and qualified counsel.

The X-waiver is gone, but other requirements remain

The federal DATA-waiver, commonly called the X-waiver, was eliminated in 2022. SAMHSA explains that, where state law permits, practitioners with the appropriate standard DEA registration and Schedule III prescribing authority may prescribe buprenorphine for OUD.

Removing the X-waiver did not remove:

• ordinary professional licensure and scope-of-practice rules
• DEA registration requirements
• the need for a legitimate medical purpose and usual course of professional practice
• telemedicine and in-person-evaluation rules
• state PDMP, documentation, consent, and prescribing requirements
• pharmacy responsibility to determine whether a prescription can be dispensed

Patient red flags and green flags

Potential red flags include a service that promises a prescription before evaluation, relies only on a questionnaire, will not identify the treating clinician, cannot explain where clinicians are licensed, or offers no plan for urgent concerns and follow-up.

More reassuring signals include real-time evaluation, visible clinician credentials, clear privacy and consent information, documented patient-location checks, transparent policies for labs and in-person needs, licensed-pharmacy coordination, and an explanation that medication is never guaranteed.

What referral partners should confirm

Hospitals, health plans, community organizations, and clinicians referring to a telehealth OUD program should ask:

1. Which practitioners and states are currently active?
2. How are identity, location, licensure, DEA registration, and PDMP checks verified?
3. How is supply under the federal pathway tracked?
4. What in-person or alternative pathway is available before the six-month limit?
5. How are pharmacies, prior authorization, and failed fills handled?
6. Which patients need emergency, inpatient, OTP, pregnancy-specific, or other higher-acuity care?
7. How is referral status shared with valid consent under HIPAA and 42 CFR Part 2?

Patients can review how online treatment works or request an evaluation. An evaluation does not guarantee legal eligibility, prescribing, a specific medication, pharmacy fulfillment, coverage, or an outcome.

Sources

• Buprenorphine Telemedicine Prescribing: Questions and Answers — SAMHSA
• DEA Announces Three New Telemedicine Rules — DEA
• Waiver Elimination (MAT Act) — SAMHSA